Pfizer Inks Nanotechnology Deal With BIND Therapeutics

Pfizer and privately held BIND Therapeutics have entered into an agreement whereby Pfizer has the option to jointly develop and commercialize selected BIND Accurin technologies, according to a press release issued today. According to BIND, Accurins use a nanoengineering platform to better target diseased tissues and cells, enhancing drug concentrations and minimizing exposure to surrounding healthy areas.

The agreement calls for Pfizer and BIND to work together in conducting the pre-clinical research, Pfizer then has the option of selecting and developing the Accurins of its choice. If Pfizer exercises its option, BIND could receive upfront and milestone payments of totaling $50 million, and an additional $160 million, if certain regulatory and sales objectives are met. Tiered royalty payments based on future sales are also possible, according to the announcement.

Rod MacKenzie, Pfizer's senior vice president and head of pharmatherapeutics R&D, said, "We look forward to working with the team at BIND Therapeutics to create targeted Accurins with the aim of optimizing the therapeutic potential of future small molecules." 

The article Pfizer Inks Nanotechnology Deal With BIND Therapeutics originally appeared on

Fool contributor Tim Brugger and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story